Kodiak Sciences Inc (NASDAQ: KOD) has experienced a decline in its stock price by -7.46 compared to its previous closing price of 3.89. However, the company has seen a fall of -19.64% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-04 that Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
Is It Worth Investing in Kodiak Sciences Inc (NASDAQ: KOD) Right Now?
KOD has 36-month beta value of 2.19. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KOD is 48.65M, and currently, short sellers hold a 4.48% ratio of that float. The average trading volume of KOD on April 18, 2024 was 922.61K shares.
KOD’s Market Performance
The stock of Kodiak Sciences Inc (KOD) has seen a -19.64% decrease in the past week, with a -36.51% drop in the past month, and a 10.77% gain in the past quarter. The volatility ratio for the week is 8.52%, and the volatility levels for the past 30 days are at 11.41% for KOD. The simple moving average for the past 20 days is -28.14% for KOD’s stock, with a 0.10% simple moving average for the past 200 days.
Analysts’ Opinion of KOD
Many brokerage firms have already submitted their reports for KOD stocks, with Goldman repeating the rating for KOD by listing it as a “Sell.” The predicted price for KOD in the upcoming period, according to Goldman is $2 based on the research report published on December 11, 2023 of the previous year 2023.
CapitalOne, on the other hand, stated in their research note that they expect to see KOD reach a price target of $12, previously predicting the price at $7. The rating they have provided for KOD stocks is “Overweight” according to the report published on November 17th, 2023.
UBS gave a rating of “Neutral” to KOD, setting the target price at $4 in the report published on July 27th of the previous year.
KOD Trading at -32.60% from the 50-Day Moving Average
After a stumble in the market that brought KOD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.27% of loss for the given period.
Volatility was left at 11.41%, however, over the last 30 days, the volatility rate increased by 8.52%, as shares sank -32.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.08% lower at present.
During the last 5 trading sessions, KOD fell by -19.64%, which changed the moving average for the period of 200-days by -47.83% in comparison to the 20-day moving average, which settled at $4.92. In addition, Kodiak Sciences Inc saw 18.42% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KOD starting from BORGESON JOHN A., who sale 2,749 shares at the price of $9.23 back on Jun 16 ’23. After this action, BORGESON JOHN A. now owns 178,077 shares of Kodiak Sciences Inc, valued at $25,373 using the latest closing price.
EHRLICH JASON, the of Kodiak Sciences Inc, sale 2,258 shares at $9.23 during a trade that took place back on Jun 16 ’23, which means that EHRLICH JASON is holding 61,924 shares at $20,841 based on the most recent closing price.
Stock Fundamentals for KOD
The total capital return value is set at -0.63. Equity return is now at value -74.22, with -45.46 for asset returns.
Based on Kodiak Sciences Inc (KOD), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at -1.4. The debt to equity ratio resting at 0.41. The interest coverage ratio of the stock is -92440.33.
Currently, EBITDA for the company is -251.37 million with net debt to EBITDA at 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.93.
Conclusion
To put it simply, Kodiak Sciences Inc (KOD) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
